SPEAKERS
Steven Gilman, Chief Scientific Officer and Executive Vice President, Research & Development, Cubist Pharmaceuticals Inc.
William Hanlon, Vice President, Head of Global Regulatory Affairs, Covance
Jean Patel, Deputy Director, Office of Antimicrobial Resistance, Centers for Disease Control and Prevention
Charlene Reed, CEO, The Foundation to Combat Antimicrobial Resistance
MODERATOR
Luke Timmerman, Biotechnology Journalist
ABSTRACTIt is widely acknowledged that antibiotic resistance is a major health crisis in the making, with some predicting a not-too-distant future of public health that looks distressingly like the distant past. But the public will and business models to address it are lagging behind awareness. How does the medical research and development paradigm need to change to solve this increasingly threatening development? What will motivate industry to invest in this space? What regulatory hurdles remain in place? What novel mechanisms are being created to address the challenge? What are the scientific hurdles we need to overcome – and how might our evolving understanding of our microbiome help?
